A detailed history of Ensign Peak Advisors, Inc transactions in Legend Biotech Corp stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 7,850 shares of LEGN stock, worth $257,323. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,850
Previous 7,850 -0.0%
Holding current value
$257,323
Previous $347,000 10.09%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $117,234 - $154,899
2,700 Added 52.43%
7,850 $378,000
Q4 2022

Feb 13, 2023

SELL
$38.8 - $55.46 $9,700 - $13,865
-250 Reduced 4.63%
5,150 $257,000
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $125,895 - $188,430
3,300 Added 157.14%
5,400 $220,000
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $6,204 - $9,636
200 Added 10.53%
2,100 $76,000
Q4 2021

Feb 11, 2022

BUY
$41.14 - $56.98 $78,166 - $108,262
1,900 New
1,900 $89,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.